"Praxis für Neuroendokrinologie mit fachärztlichen Endokrinologen +++ Einige typische Schwerpunkte in unseren Sprechstunden sind Diagnose und Behandlung bei: Adipositas Diabetes Typ 2 Endokriner Bluthochdruck Geschlechtsentwicklungsstörungen Hormonelle Probleme bei psychiatrischen Erkrankungen Hypophysenerkrankungen, Hormoninsuffizienz nach Schädel-Hirn-Trauma Nebennierenerkrankungen Osteoporose PCO-Syndrom Schilddrüsenerkrankungen Störungen der Geschlechtshormone bei Mann und Frau Transsexualität. Für Patientinnen und Patienten, Angehörige und Interessierte bieten wir Ernährungskurse zur Stoffwechseloptimierung an."

During the past decade, MEDICOVER Neuroendokrinologie conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "MEDICOVER Neuroendokrinologie" are "Acromegaly" (4 trials) and "Chronic Adrenal Insufficiency" (1 trials). Many other conditions were trialed in "MEDICOVER Neuroendokrinologie" in a lesser frequency.

Most popular intervention types in "MEDICOVER Neuroendokrinologie" are "Drug" (4 trials). Other intervention types were less common.

The name of intervention was led by "CAM2029 (octreotide subcutaneous depot)" (2 trials), "Paltusotine" (2 trials), "Matching placebo" (1 trials) and "Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "MEDICOVER Neuroendokrinologie" are 5 trials for "All" genders.

Currently, there are NaN active trials in "MEDICOVER Neuroendokrinologie". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in MEDICOVER Neuroendokrinologie, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in MEDICOVER Neuroendokrinologie, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".